Chimeric antigen receptor T-cell (CAR-T) cell therapy in Hungary in paediatric acute lymphoblastic leukaemia (ALL) and adult diffuse large B-cell lymphoma (DLBCL) disorders (Q3911376): Difference between revisions
Jump to navigation
Jump to search
(Removed claims) |
(Changed an Item: importing one item from Hungary) |
||||||||||||||
Property / co-financing rate | |||||||||||||||
94.999998 percent
| |||||||||||||||
Property / co-financing rate: 94.999998 percent / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / fund | |||||||||||||||
Property / fund: European Social Fund / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / instance of | |||||||||||||||
Property / instance of: Kohesio project / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / financed by | |||||||||||||||
Property / financed by: European Union / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / country | |||||||||||||||
Property / country: Hungary / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / start time | |||||||||||||||
1 February 2021
| |||||||||||||||
Property / start time: 1 February 2021 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / end time | |||||||||||||||
1 February 2023
| |||||||||||||||
Property / end time: 1 February 2023 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / beneficiary name (string) | |||||||||||||||
DÉL-PESTI CENTRUMKÓRHÁZ-ORSZÁGOS HEMATOLÓGIAI ÉS INFEKTOLÓGIAI INTÉZET | |||||||||||||||
Property / beneficiary name (string): DÉL-PESTI CENTRUMKÓRHÁZ-ORSZÁGOS HEMATOLÓGIAI ÉS INFEKTOLÓGIAI INTÉZET / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / EU contribution | |||||||||||||||
3,593,115.942 Euro
| |||||||||||||||
Property / EU contribution: 3,593,115.942 Euro / rank | |||||||||||||||
Preferred rank | |||||||||||||||
Property / EU contribution: 3,593,115.942 Euro / qualifier | |||||||||||||||
exchange rate to Euro: 0.00276521 Euro
| |||||||||||||||
Property / EU contribution: 3,593,115.942 Euro / qualifier | |||||||||||||||
point in time: 3 December 2021
| |||||||||||||||
Property / EU contribution | |||||||||||||||
1,299,400,748 forint
| |||||||||||||||
Property / EU contribution: 1,299,400,748 forint / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / location (string) | |||||||||||||||
Budapest, Budapest | |||||||||||||||
Property / location (string): Budapest, Budapest / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / programme | |||||||||||||||
Property / programme: Human Resources Development - HU - ESF/ERDF / rank | |||||||||||||||
Normal rank |
Revision as of 14:01, 3 December 2021
Project Q3911376 in Hungary
Language | Label | Description | Also known as |
---|---|---|---|
English | Chimeric antigen receptor T-cell (CAR-T) cell therapy in Hungary in paediatric acute lymphoblastic leukaemia (ALL) and adult diffuse large B-cell lymphoma (DLBCL) disorders |
Project Q3911376 in Hungary |
Statements
1,299,400,748 forint
0 references
94.999998 percent
0 references
1 February 2021
0 references
1 February 2023
0 references
DÉL-PESTI CENTRUMKÓRHÁZ-ORSZÁGOS HEMATOLÓGIAI ÉS INFEKTOLÓGIAI INTÉZET
0 references
Budapest, Budapest
0 references
Identifiers
EFOP-5.2.6-20-2020-00010
0 references